These findings highlight a mechanistically informed therapeutic strategy with clear translational relevance for MLL-r AML and provide strong rationale for clinical testing of menin-LSD1 inhibitor combinations in MLL-r acute leukemia. Here, KMT2A is linked to acute myeloid leukemia.